Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma

Published:2017-06-02 Issue:1 Volume:59 Page:42-48
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Milone Giuseppe¹,Martino Massimo²^ORCID,Leotta Salvatore¹,Spadaro Andrea¹,Zammit Valentina¹,Cupri Alessandra¹,Avola Giuseppe¹,Camuglia Maria Grazia¹,Di Marco Annalia¹,Scalzulli Potito³,Morelli Mara⁴,Olivieri Attilio⁵,Tripepi Giovanni⁶

Affiliation:

1. Hematology and BMT UNIT, Azienda Policlinico Vittorio Emanuele, Catania, Italy;

2. Hematology and BMT UNIT, Ospedale Bianco Melacrino Morelli, Reggio Calabria, Italy;

3. Hematology and BMT UNIT, Ospedale Sollievo Sofferenza, San Giovanni Rotondo, Italy;

4. Hematology and BMT UNIT, H San Raffaele, Milano, Italy;

5. Hematology and BMT UNIT, Universita delle Marche, Ancona, Italy;

6. Istituto di Fisiologia Clinica, CNR, Reggio Calabria, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1324161

Reference22 articles.

1. Salvage Second Hematopoietic Cell Transplantation in Myeloma

2. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

3. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies

4. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

5. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese experience in hematopoietic stem cell mobilization and collection in lymphoma patients: a retrospective cohort study;2024-04-22

2. On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost;Frontiers in Oncology;2024-01-17

3. Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection;Transfusion and Apheresis Science;2023-12

4. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation;Transfusion Medicine and Hemotherapy;2023

5. Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient;Clinical Lymphoma Myeloma and Leukemia;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3